| Revision as of 19:48, 16 December 2003 editElBenevolente (talk | contribs)1,884 edits added fda indications, deleted incorrect information that zyprexa was marketed as anti-parkonsonian← Previous edit | Revision as of 05:30, 31 December 2003 edit undoElBenevolente (talk | contribs)1,884 editsNo edit summaryNext edit → | ||
| Line 1: | Line 1: | ||
| '''Please note: ]'''. | |||
| ---- | |||
| '''Olanzapine''' ('''Zyprexa<sup>®</sup>''') is one of the ] ] ]s. Olanzapine has been ] approved for treatment of ] and ] in ]. The ] ] ''Prozac Spotlight'' argues that a ] study demonstrated that the drug was ineffective in treatment of Parkinson's disease. | '''Olanzapine''' ('''Zyprexa<sup>®</sup>''') is one of the ] ] ]s. Olanzapine has been ] approved for treatment of ] and ] in ]. The ] ] ''Prozac Spotlight'' argues that a ] study demonstrated that the drug was ineffective in treatment of Parkinson's disease. | ||
Revision as of 05:30, 31 December 2003
Please note: Misplaced Pages does not give medical advice.
Olanzapine (Zyprexa) is one of the atypical antipsychotic medications. Olanzapine has been FDA approved for treatment of schizophrenia and mania in bipolar disorder. The anti-psychiatry website Prozac Spotlight argues that a 1999 study demonstrated that the drug was ineffective in treatment of Parkinson's disease.
Side Effects
Common side effects include muscle-rigidity, muscle-stiffness, muscle-twitches, restlesness, sedation, and weight-gain. Olanzapine is reported to cause tardive dyskinesia and neurological malignant syndrome.
Olanzapine is manufactured by Eli Lilly (NYSE: LLY).